March 8, 2023
The possible play for Abbott
Now that Abbott has “cleared” the AID hurdle for Libre questions abound as to what’s next. As we noted yesterday Abbott could buy either Insulet or Tandem. Keep in mind Abbott has two goals here; increase Libre sales and stymie Dexcom from gaining more users. Abbott has also made it clear they are not opposed to acquisitions. The question becomes are Insulet and Tandem the only options here.
Given that 61% of Libre revenue is outside the US the shortest distance between gaining more libre sales is to acquire either a company that is already strong overseas or one . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
